Nicole Shockcor, Sakib Adnan, Ariel Siegel, Sami Tannouri, Mark Kligman. University of Maryland
Introduction: Over the last decade, United States healthcare providers dispensed over 200 million opioid prescriptions annually for chronic pain. Here we aimed to determine the effect of prescription opioid use on weight loss post laparoscopic Roux-en-Y gastric bypass (LRYGB) as well as laparoscopic sleeve gastrectomy (LSG).
Methods: We completed a retrospective review of chronic prescription opioid use in 1177 consecutive patients undergoing primary bariatric surgery at a single institution. Patients were grouped into chronic prescription opioid users (OU), defined as ongoing opioid use for >3 months at the time of surgery, and non-users (NU), defined as no opioid use prior to surgery. Patients undergoing remedial operations (conversions or revisions), and those lost to follow up were excluded.
Results: In the 1177 patients included in this analysis, 133 (11.3%) were identified as chronic prescription opioid users. 465 (39.5%) underwent LSG and 713 (60.6%) underwent LRYGB with similar rates in both groups. At 2 months OU patients lost on average 54.88 lb, similar to NU patients 56.8 lb (p-value 0.402). Similar outcomes persisted long-term at 1 year follow up with average weight loss in the OU group 93.46 lb vs NU 97.91 lb (p-value 0.458). Postoperative complications and rates of follow up were studied and similar between groups.
Conclusions: A significant proportion (11.3%) of bariatric patients have active narcotic prescriptions, and given the ongoing opioid epidemic, understanding the short and long-term effects on surgical patients is key. Initial analysis here supports similar weight loss outcomes in prescription opioid users as compared to non-users.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 95968
Program Number: P129
Presentation Session: Poster Session (Non CME)
Presentation Type: Poster